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Objective The aim of this study was to provide additional
insight into the role of fibrinogen in coronary artery disease
by investigating the associations between plasma
fibrinogen with both degree and composition of coronary
atherosclerosis as determined by virtual histology-
intravascular ultrasound.
Patients and methods In 581 patients undergoing
coronary angiography for acute coronary syndrome (ACS) or
stable angina pectoris, preprocedural blood samples were
drawn for fibrinogen, C-reactive protein (CRP), interleukin-6,
and plasminogen activator inhibitor-1 measurements, and
virtual histology-intravascular ultrasound of a nonculprit
coronary artery was performed. The degree [plaque volume,
plaque burden (PB), and lesions with PB≥ 70%] and the
composition of coronary atherosclerotic plaque (fibrous,
fibrofatty, dense calcium, necrotic core tissue, and thin-cap
fibroatheroma lesions) were assessed.
Results Fibrinogen showed a tendency toward a positive
association with PB [β (95% CI): 2.55 (−0.52–5.61) increase in
PB per ln(g/l) fibrinogen, P=0.09], which was driven
significantly by an association in the ACS subgroup [β (95%
CI): 4.11 (0.01–8.21) increase in PB per ln(g/l) fibrinogen,
P=0.049]. Fibrinogen was also related to the presence of
lesions with PB 70% or more in both the full cohort [OR (95%
CI): 2.27 (1.17–4.43), P=0.016] and ACS patients [OR (95%CI):
2.92 (1.17–7.29), P=0.022]. All associations were independent
of established cardiovascular risk factors, but not CRP.
Interleukin-6 and plasminogen activator inhibitor-1 did not
provide incremental value to fibrinogen when examining the
associations with degree of atherosclerosis. Substantial
associations with plaque composition were absent.
Conclusion Fibrinogen is associated with degree of
coronary atherosclerosis, especially in ACS patients.
However, whether this association is independent of CRP
might be questioned and needs further investigation. Coron
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Introduction
Elevated plasma fibrinogen levels have been associated
with coronary events both in apparently healthy indivi-
duals [1–3] and in patients with manifest coronary artery
disease (CAD) [4–7]. Underlying mechanisms that may
account for this association have not been fully eluci-
dated as yet, but fibrinogen is known to play an important
role in thrombosis [8] and might as well influence the
progression of atherosclerotic plaque formation [9,10]. In
addition, clinical evidence has shown that fibrinogen is
correlated with the severity of atherosclerosis on both
coronary angiography and carotid ultrasonography [11–15].
These noninvasive imaging techniques evaluate the
unobstructed part of the lumen and have not contributed
toward elucidating potential mechanisms of the involve-
ment of fibrinogen in atherosclerosis. In contrast, invasive
assessment of coronary plaque by virtual histology-
intravascular ultrasound (VH-IVUS) not only accurately
quantifies coronary atherosclerosis but also enables in-vivo
analysis of coronary plaque composition as well as plaque
vulnerability. Thus, this technique provides information on
the structure and composition of the arterial wall itself and
could add insights into the pathophysiology of coronary
atherosclerosis [16].
Until now, the association between fibrinogen and in-
vivo coronary plaque characteristics has only been
examined in two IVUS studies [17,18]. The first study
had a modest study sample size of 60 patients and
applied grayscale IVUS to quantify coronary athero-
sclerosis, which did not allow for assessment of the
composition and vulnerability of the coronary plaques
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[17]. The second study did use VH-IVUS, but again had
limited sample size (only 75 patients) [18]. Furthermore,
although this study examined necrotic core (NC), it did
not assess plaque vulnerability by determining thin-cap
fibroatheromas (TCFAs) [18].
Therefore, we investigated the association of plasma
fibrinogen with the degree, composition, and vulner-
ability of coronary atherosclerosis as determined by VH-
IVUS, as well as with 1-year cardiovascular outcome, in a
relatively large study population consisting of 581
patients undergoing coronary angiography. In addition, to
provide a broader view on the pathophysiological rela-
tionship between fibrinogen and coronary atherosclerosis,
we examined the incremental value of the inflammatory
and prothrombotic markers C-reactive protein (CRP),
interleukin-6 (IL-6), and plasminogen activator inhibitor-
1 (PAI-1) to fibrinogen.
Patients and methods
The rationale and design of the European Collaborative
Project on Inflammation and Vascular Wall Remodeling in
Atherosclerosis – Intravascular Ultrasound (ATHERO
REMO-IVUS) study have been approved by the medical
ethics committee of the Erasmus MC (Rotterdam, the
Netherlands) and are described in detail elsewhere [19]. The
study is registered on ClinicalTrials.gov, number NCT0
1789411. Briefly, 581 patients undergoing diagnostic coronary
angiography or percutaneous coronary intervention for acute
coronary syndrome (ACS) or stable angina pectoris (SAP) were
included. Written informed consent was obtained from all
included patients. Baseline clinical and procedural character-
istics were derived from medical records. Blood plasma sam-
ples were drawn before the procedure and stored at a
temperature of −80°C. Frozen EDTA-plasma samples were
transported under controlled conditions to Myriad RBM
(Austin, Texas, USA), where fibrinogen, IL-6, and PAI-1
levels were measured successfully in 570 samples (ACS,
n=309; SAP, n=261) using a validated, quantitative, multi-
plexed immunoassay (Custom HumanMAP; Myriad RBM).
CRP measurements were performed in serum samples at the
clinical laboratory of Erasmus MC using an immunoturbidi-
metric high-sensitivity assay (Roche Diagnostics Ltd,
Rotkreuz, Switzerland) on the Cobas 8000 Modular Analyzer
Platform (Roche Diagnostics Ltd). Coefficients of variation
were 8% or less, 10% or less, 11% or less, and 4% or less for
fibrinogen, IL-6, PAI-1, and CRP, respectively. Following the
standard coronary angiography, VH-IVUS data were acquired
in a nonculprit coronary artery with the Volcano s5/s5i Imaging
System (Volcano Corp., San Diego, California, USA) using a
Volcano Eagle Eye Gold IVUS catheter (20MHz) [19]. The
degree and composition of the atherosclerotic plaque were
assessed offline in a dedicated core-lab as described previously
[19]. Plaque volume was defined as the total volume of the
external elastic membrane occupied by atheroma and was
normalized for the length of the imaged segment. Plaque
burden (PB) was defined as plaque and media cross-sectional
area divided by external elastic membrane cross-sectional area
and is presented as a percentage. Atherosclerotic plaque
composition was characterized into fibrous (FI), fibrofatty,
dense calcium, and NC. Three types of high-risk lesions were
identified: (i) VH-IVUS-derived TCFA lesions (presence of
>10% confluent NC in direct contact with the lumen); (ii)
lesions with large PB (≥70%); and (iii) lesions with a minimal
luminal area 4.0mm2 or less.
Clinical follow-up started at inclusion and lasted 1 year.
The primary clinical endpoint consisted of major adverse
cardiovascular events (MACEs), which was a composite
of death, ACS, or unplanned coronary revascularization
[19]. ACS was defined as the clinical diagnosis of non-
ST-segment elevation myocardial infarction or unstable
angina pectoris [20,21]. Unplanned coronary revascular-
ization was defined as any repeat percutaneous coronary
intervention or coronary artery bypass grafting that was
not foreseen at the index procedure. Endpoints were
adjudicated by a clinical events committee on the basis of
original source data.
Normally distributed continuous variables are presented
as mean ± SD, whereas non-normally distributed con-
tinuous variables are presented as median (interquartile
range). Categorical variables are presented as numbers
and percentages. Variables with non-normal distributions,
determined by visual inspection of the histograms, were
natural logarithmically (ln) transformed or were trans-
formed using the square root for further analyses. First,
statistical analyses were carried out in the full cohort.
Subsequently, they were stratified on indication for
catheterization (ACS vs. SAP) to account for potential
differences in pathophysiology. Associations of fibrino-
gen with segment VH-IVUS parameters were examined
using linear regression analyses with continuous ln-
transformed fibrinogen as the independent variable.
The results are presented as β increase in (transformed)
segment VH-IVUS parameter per unit increase in ln-
transformed fibrinogen concentration, with 95% con-
fidence intervals (CIs). Logistic regression analyses were
carried out for associations between fibrinogen and the
presence of high-risk lesions with continuous ln-
transformed fibrinogen as the independent variable.
The results are presented as odds ratios (ORs) per unit
increase in ln-transformed fibrinogen concentration, with
95% CIs. All statistical analyses were carried out uni-
variably (model 1) and multivariably (models 2 and 3).
Potential confounders were selected on the basis of
previous literature (age, sex, smoking, diabetes mellitus,
dyslipidemia, hypertension, indication for catheteriza-
tion) and entered as covariates into the multivariable
models (model 2). Subsequently, CRP was added to the
models (model 3) as CRP is the most widely studied
inflammatory marker in cardiovascular disease and has
been suggested to carry similar predictive value for
MACE as fibrinogen [22].
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Afterwards, we examined whether the inflammatory
markers IL-6 and CRP and the prothrombotic marker
PAI-1 provide incremental value to elevated levels of
fibrinogen with respect to the degree of atherosclerosis.
For this purpose, these markers were dichotomized [CRP
and PAI-1: below and above the median; IL-6: detect-
able (37.7%) vs. nondetectable (62.3%) levels], and
degree of atherosclerosis was examined in patients
according to both the categories of these markers and
dichotomized categories of fibrinogen (above and below
median). ANOVA trend tests were used to discern trends
across the categories.
Finally, we examined associations of fibrinogen with
clinical endpoints after 1 year of follow-up with Cox
proportional hazard regression analyses.
Results
Baseline clinical and procedural characteristics are pre-
sented in Table 1. The mean ±SD age of the patients
was 61.5 ± 11.4 years (75% were men); 54% of the
patients were admitted with ACS and 46% had SAP. The
median (interquartile range) fibrinogen level was 3.5
(2.9–4.4) g/l in the full cohort. In ACS and SAP patients,
this was 3.6 (3.0–4.5) and 3.4 (2.8–4.3) g/l, respectively
(P= 0.028).
The results of the univariable and multivariable analyses
for the associations between plasma fibrinogen level and
degree and composition of coronary atherosclerosis are
shown in Table 2 for the full cohort, in Table 3 for ACS,
and in Table 4 for SAP. The degree of atherosclerosis in
each group is graphically presented per fibrinogen tertile
in Figs 1 and 2. There seemed to be a trend toward
higher segment PB (P for trend= 0.008 full cohort; P for
trend= 0.014 ACS subgroup) and a higher prevalence of
lesions with PB 70% or more (P for trend= 0.002 full
cohort; P for trend= 0.001 ACS subgroup) with increasing
fibrinogen levels. Specifically, fibrinogen showed a ten-
dency toward a positive association with segment PB [β
(95% CI): 2.55 (− 0.52–5.61) increase in %PB per ln(g/l)
fibrinogen, P= 0.09] in the full cohort (Table 2, model 2,
Fig. 1), which was driven by a significant association in
the ACS subgroup [β (95% CI): 4.11 (0.01–8.21) increase
in %PB per ln(g/l) fibrinogen, P= 0.049] (Table 3, model
2, Fig. 1). Fibrinogen was also associated with the pre-
sence of lesions with PB 70% or more in both the full
cohort [OR (95% CI): 2.27 (1.17–4.43), P= 0.016]
(Table 2, model 2, Fig. 2) and ACS patients [OR (95%
CI): 2.92 (1.17–7.29), P= 0.022] (Table 3, model 2,
Fig. 2). This association did not reach statistical sig-
nificance in the SAP subgroup [OR (95% CI): 1.69
(0.62–4.59), P= 0.30] (Table 4, model 2, Fig. 2). After
additional adjustment for CRP, statistical significance
was no longer reached for any of the associations (model 3
in Tables 2–4).
With respect to the composition and vulnerability of
atherosclerosis, in the full cohort, fibrinogen was asso-
ciated positively with NC volume [β (95% CI): 0.83
(0.11–1.54) mm3 increase in NC volume per ln(g/l)
fibrinogen, P= 0.024] and FI tissue [β (95% CI): 0.99
(0.01–1.96) mm3 increase in FI volume per ln(g/l) fibri-
nogen, P= 0.047] (Table 2, model 2). However, fibrino-
gen was not associated with the presence of VH-TCFA
lesions (i.e. rupture-prone coronary plaques). No asso-
ciations with composition were present in the ACS and
SAP subgroups. After additional adjustment for CRP,
again, statistical significance was no longer reached for
any of the associations (model 3 in Tables 2–4).
We have described the individual associations of CRP,
IL-6, and PAI-1 with the degree, composition, and vul-
nerability of atherosclerosis in this cohort in earlier
reports [23–25]. Briefly, we found that CRP was asso-
ciated with degree, but not composition or vulnerability
of atherosclerosis, and IL-6 and PAI-1 did not show sig-
nificant associations with any of the plaque character-
istics. In the present study, trend analysis showed that
patients with both elevated fibrinogen and CRP levels
have higher segment PB (P for trend= 0.041) and a
higher prevalence of lesions with PB 70% or more (P for
Table 1 Baseline patient and procedural characteristics
Full cohort
(n=570)
ACS patients
(n=309)
SAP patients
(n=261)
Patient characteristics
Age (mean ±SD) (years) 61.5 ±11.4 59.7 ±11.9 63.6 ±10.3
Male sex [n (%)] 430 (75.4) 227 (73.5) 203 (77.8)
Hypertension [n (%)] 295 (51.8) 134 (43.4) 161 (61.7)
Dyslipidemia [n (%)] 317 (55.6) 137 (44.3) 180 (69.0)
Diabetes mellitus [n (%)] 99 (17.4) 40 (12.9) 59 (22.6)
Positive family history
[n (%)]
293 (51.5) 140 (45.5) 153 (58.6)
Smoking [n (%)] 164 (28.8) 115 (37.2) 49 (18.8)
Peripheral artery disease
[n (%)]
36 (6.3) 12 (3.9) 24 (9.2)
Previous myocardial
infarction [n (%)]
184 (32.3) 80 (25.9) 104 (39.8)
Previous PCI [n (%)] 185 (32.5) 57 (18.4) 128 (49.0)
Previous CABG [n (%)] 18 (3.2) 7 (2.3) 11 (4.2)
Previous stroke [n (%)] 23 (4.0) 10 (3.2) 13 (5.0)
History of renal
insufficiency [n (%)]
32 (5.6) 13 (4.2) 19 (7.3)
Fibrinogen [median
(interquartile range)]
(g/l)
3.5 (2.9–4.4) 3.6 (3.0–4.5) 3.4 (2.8–4.3)
Procedural characteristics [n (%)]
PCI performed 501 (87.9) 287 (92.9) 214 (82.0)
Indication for catheterization
ACS 309 (54.2) 309 (100) NA
Myocardial
infarction
159 (27.9) 159 (51.5) NA
SAP 261 (45.8) NA 261 (100)
Coronary artery disease
No significant
stenosis
42 (7.4) 18 (5.8) 24 (9.2)
One-vessel disease 301 (52.8) 168 (54.4) 133 (51.0)
Two-vessel disease 166 (29.1) 88 (28.5) 78 (29.9)
Three-vessel
disease
61 (10.7) 35 (11.3) 26 (10.0)
ACS, acute coronary syndrome; CABG, coronary artery bypass graft surgery; NA,
not applicable; PCI, percutaneous coronary intervention; SAP, stable angina
pectoris.
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Table 2 Association between fibrinogen and virtual histology-intravascular ultrasound segment and lesion characteristics in the full cohort
(n= 570)
Model 1 (linear regression)a Model 2 (linear regression)b Model 3 (linear regression)c
VH-IVUS segment characteristics β (95% CI) P-value β (95% CI) P-value β (95% CI) P-value
Degree of atherosclerosis
Plaque volume (mm3)d 0.12 (−0.04 to 0.28) 0.15 0.12 (−0.04 to 0.28) 0.15 0.02 (−0.15 to 0.20) 0.79
Plaque burden (%) 2.53 (−0.48 to 5.54) 0.10 2.55 (−0.52 to 5.61) 0.09 0.84 (−2.49 to 4.17) 0.62
Composition of atherosclerosis
FI volume (mm3)d 1.01 (0.06 to 1.96) 0.037 0.99 (0.01 to 1.96) 0.047 0.46 (−0.60 to 1.52) 0.39
FF volume (mm3)d 0.14 (−0.14 to 0.42) 0.32 0.15 (−0.13 to 0.43) 0.30 0.002 (−0.31 to 0.31) 0.99
NC volume (mm3)d 0.81 (0.11 to 1.51) 0.024 0.83 (0.11 to 1.54) 0.024 0.46 (−0.32 to 1.24) 0.25
DC volume (mm3)d 0.18 (−0.13 to 0.48) 0.25 0.21 (−0.10 to 0.52) 0.18 0.07 (−0.27 to 0.41) 0.68
Model 1 (logistic regression)a Model 2 (logistic regression)b Model 3 (logistic regression)c
VH-IVUS high-risk lesion
characteristics OR (95% CI) P-value OR (95% CI) P-value OR (95% CI) P-value
Degree of atherosclerosis
≥1 lesion with MLA≤4.0 mm2 0.59 (0.32–1.07) 0.08 0.59 (0.32–1.10) 0.10 0.60 (0.30–1.19) 0.14
≥1 lesion with plaque burden
≥70%
2.15 (1.12–4.11) 0.021 2.27 (1.17–4.43) 0.016 1.90 (0.91–3.97) 0.09
Composition of atherosclerosis
≥1 TCFA 1.02 (0.59–1.75) 0.95 0.93 (0.53–1.63) 0.80 0.83 (0.45–1.53) 0.54
β Indicates the increase in each (transformed) VH-IVUS segment parameter per unit increase in the logarithm (ln)-transformed fibrinogen level. OR in the presence of high-
risk lesions per unit increase in the ln-transformed fibrinogen level.
CI, confidence interval; DC, dense calcium; FF, fibrofatty; FI, fibrous; MLA, minimal lumen area; NC, necrotic core; OR, odds ratio; TCFA, thin-cap fibroatheroma; VH-IVUS,
virtual histology-intravascular ultrasound.
aModel 1 (univariable) adjusted for age and sex.
bModel 2 (multivariable) adjusted for established risk factors (age, sex, smoking, diabetes mellitus, hypertension, and dyslipidemia) and indication for catheterization.
cModel 3 (multivariable) adjusted for established risk factors, indication for catheterization, and additionally for C-reactive protein.
dVariables with a non-normal distribution were transformed by the natural ln or square root.
Table 3 Association between fibrinogen and virtual histology-intravascular ultrasound segment and lesion characteristics in acute coronary
syndrome patients
ACS patients (n=309)
Model 1 (linear regression)a Model 2 (linear regression)b Model 3 (linear regression)c
VH-IVUS segment characteristics β (95% CI) P-value β (95% CI) P-value β (95% CI) P-value
Degree of atherosclerosis
Plaque volume (mm3)d 0.14 (−0.08 to 0.35) 0.21 0.13 (−0.09 to 0.35) 0.25 0.05 (−0.20 to 0.29) 0.71
Plaque burden (%) 4.47 (0.43 to 8.51) 0.030 4.11 (0.01 to 8.21) 0.049 2.26 (−2.28 to 6.81) 0.33
Composition of atherosclerosis
FI volume (mm3)d 0.99 (−0.28 to 2.26) 0.13 0.90 (−0.39 to 2.19) 0.17 0.32 (−1.11 to 1.75) 0.66
FF volume (mm3)d 0.19 (−0.18 to 0.56) 0.31 0.20 (−0.17 to 0.58) 0.29 0.05 (−0.37 to 0.47) 0.82
NC volume (mm3)d 0.71 (−0.22 to 1.63) 0.13 0.65 (−0.29 to 1.59) 0.17 0.32 (−0.72 to 1.37) 0.54
DC volume (mm3)d 0.25 (−0.15 to 0.65) 0.22 0.26 (−0.15 to 0.67) 0.22 0.16 (−0.29 to 0.62) 0.48
Model 1 (logistic regression)a Model 2 (logistic regression)b Model 3 (logistic regression)c
VH-IVUS high-risk lesion
characteristics OR (95% CI) P-value OR (95% CI) P-value OR (95% CI) P-value
Degree of atherosclerosis
≥1 lesion with MLA≤4.0 mm2 0.75 (0.33–1.72) 0.50 0.72 (0.30–1.74) 0.47 0.81 (0.30–2.14) 0.67
≥1 lesion with plaque
burden≥70%
2.84 (1.17–6.91) 0.022 2.92 (1.17–7.29) 0.022 2.18 (0.77–6.18) 0.14
Composition of atherosclerosis
≥1 TCFA 0.85 (0.42–1.75) 0.66 0.77 (0.37–1.61) 0.48 0.68 (0.30–1.55) 0.36
β Indicates the increase in each VH-IVUS segment parameter per unit increase in the logarithm (ln)-transformed fibrinogen level. OR in the presence of high-risk lesions per
unit increase in the ln-transformed fibrinogen level.
ACS, acute coronary syndrome; CI, confidence interval; DC, dense calcium; FF, fibrofatty; FI, fibrous; MLA, minimal lumen area; NC, necrotic core; OR, odds ratio; TCFA,
thin-cap fibroatheroma; VH-IVUS, virtual histology-intravascular ultrasound.
aModel 1 (univariable) adjusted for age and sex.
bModel 2 (multivariable) adjusted for established risk factors (age, sex, smoking, diabetes mellitus, hypertension, and dyslipidemia).
cModel 3 (multivariable) adjusted for established risk factors and additionally for C-reactive protein.
dVariables with a non-normal distribution were transformed by the natural ln or square root.
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trend= 0.090), especially in the ACS subgroup (P for
trend= 0.001) (Figs 3 and 4). Such a trend could not be
found for fibrinogen in combination with IL-6 or PAI-1
(Figs 5–8).
With respect to clinical outcome (results not shown), in the
full cohort as well as in the individual ACS and SAP sub-
groups, no association was found between fibrinogen and
MACE. A borderline significant univariable association
Table 4 Association between fibrinogen and virtual histology-intravascular ultrasound segment and lesion characteristics in stable angina
pectoris patients
SAP patients (n=261)
Model 1 (linear regression)a Model 2 (linear regression)b Model 3 (linear regression)c
VH-IVUS segment characteristics β (95% CI) P-value β (95% CI) P-value β (95% CI) P-value
Degree of atherosclerosis
Plaque volume (mm3)d 0.12 (−0.13 to 0.36) 0.35 0.09 (−0.16 to 0.34) 0.50 −0.005 (−0.27 to 0.26) 0.97
Plaque burden (%) 0.64 (−3.93 to 5.20) 0.78 −0.14 (−4.85 to 4.58) 0.95 −1.32 (−6.29 to 3.65) 0.60
Composition of atherosclerosis
FI volume (mm3)d 1.17 (−0.31 to 2.65) 0.12 1.02 (−0.50 to 2.54) 0.19 0.62 (−0.99 to 2.22) 0.45
FF volume (mm3)d 0.14 (−0.28 to 0.57) 0.51 0.05 (−0.38 to 0.49) 0.81 −0.06 (−0.52 to 0.40) 0.80
NC volume (mm3)d 1.02 (−0.08 to 2.12) 0.07 0.91 (−0.22 to 2.04) 0.12 0.59 (−0.61 to 1.79) 0.33
DC volume (mm3)d 0.16 (−0.32 to 0.63) 0.51 0.10 (−0.39 to 0.59) 0.68 −0.04 (−0.55 to 0.47) 0.88
Model 1 (logistic regression)a Model 2 (logistic regression)b Model 3 (logistic regression)c
VH-IVUS high-risk lesion
characteristics OR (95% CI) P-value OR (95% CI) P-value OR (95% CI) P-value
Degree of atherosclerosis
≥1 lesion with MLA≤4.0 mm2 0.47 (0.19–1.15) 0.10 0.41 (0.16–1.05) 0.06 0.41 (0.15–1.09) 0.07
≥1 lesion with plaque
burden≥70%
1.81 (0.69–4.77) 0.23 1.69 (0.62–4.59) 0.30 1.61 (0.56–4.66) 0.38
Composition of atherosclerosis
≥1 TCFA 1.13 (0.48–2.65) 0.79 1.07 (0.44–2.59) 0.89 0.98 (0.38–2.52) 0.97
β Indicates the increase in each VH-IVUS segment parameter per unit increase in logarithm (ln)-transformed fibrinogen level. OR in presence of high-risk lesions per unit
increase in ln-transformed fibrinogen level.
CI, confidence interval; DC, dense calcium; FF, fibrofatty; FI, fibrous; MLA, minimal lumen area; NC, necrotic core; OR, odds ratio; SAP, stable angina pectoris; TCFA, thin-
cap fibroatheroma; VH-IVUS, virtual histology-intravascular ultrasound.
aModel 1 (univariable) adjusted for age and sex.
bModel 2 (multivariable) adjusted for established risk factors (age, sex, smoking, diabetes mellitus, hypertension, and dyslipidemia).
cModel 3 (multivariable) adjusted for established risk factors and additionally for C-reactive protein.
dVariables with a non-normal distribution were transformed by the natural ln or square root.
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of lesions with plaque burden 70% or more per category of IL-6
(detectable or nondetectable) and fibrinogen (above or under median)
together in the full cohort and stratified groups. ACS, acute coronary
syndrome; IL-6, interleukin-6; SAP, stable angina pectoris.
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between fibrinogen and the secondary, composite end-
point of death, or ACS was present in the full cohort [HR
(95% CI): 2.69 (0.99–7.30), P= 0.052]. After adjustment for
age and sex, the association became nonsignificant,
although the effect estimate remained materially the same
[HR (95% CI): 2.36 (0.80–6.93), P= 0.12]. With further
adjustment for CRP, the HR became closer to the null
[HR (95% CI): 0.73 (0.20–2.64), P=0.64].
Discussion
This is the first large study that has investigated the asso-
ciation between plasma fibrinogen level and the degree,
composition, and vulnerability of coronary atherosclerotic
plaque as assessed by VH-IVUS. Thus, our study provides
additional insight into the nature of the relationship
between fibrinogen and CAD. We found that fibrinogen
was associated with PB and presence of large lesions, both
significantly driven by patients presenting with ACS.
Conversely, we could not find substantial associations
between fibrinogen and atherosclerotic plaque composi-
tion, including VH-IVUS-derived TCFA lesions (i.e.
rupture-prone coronary plaques). The latter agrees with an
earlier study, which could not find an association between
fibrinogen and rupture-prone carotid plaques on ultra-
sonography [26]. Altogether, these findings might indicate
that fibrinogen plays a pathogenic role in the progression of
atherosclerotic plaque formation rather than in plaque
vulnerability, especially in ACS patients.
Although several studies using different modalities have
examined the association between fibrinogen and ather-
osclerosis, so far, only two studies have applied the IVUS
technique [17,18]. Hartmann et al. [17] examined this
association with grayscale IVUS in only 60 patients and
concluded that fibrinogen levels correlate with plaque
progression on IVUS, which is in line with our findings.
Yet, the grayscale IVUS technique did not enable
examination of plaque composition or plaque vulner-
ability. The other study, published recently by Corban
et al. [18], used the VH-IVUS technique as we did, but
the study size was again modest with 75 patients. They
concluded that fibrinogen degradation products are
associated with larger plaques that have a larger NC.
Although they did not stratify their study population by
clinical diagnosis (ACS vs. SAP), their findings concur
with our results in the full cohort. Here, the authors
suggest that fibrinogen may play a role in plaque vul-
nerability, which should be confirmed in studies that
determined TCFAs. However, as the study population
was relatively small and consisted of patients with non-
obstructive CAD, this study contained a low number of
TCFAs. Therefore, the authors could not investigate
further whether fibrinogen is associated with plaque
vulnerability. In our study, with a relatively large sample
size, we could examine the relationship between fibri-
nogen and TCFAs, but the results did not confirm a
relationship with fibrinogen. Therefore, we hypothesize
that fibrinogen might rather play a pathogenic role in
atherosclerotic plaque formation than in plaque
vulnerability.
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A potential association of fibrinogen with degree of cor-
onary plaque is in line with earlier studies, proposing a
mechanism by which fibrinogen, as a major determinant
of thrombus formation, could directly contribute toward
the progression of coronary atherosclerosis [8,27].
Fibrinogen is believed to be involved in an underlying
process of multiple consecutive mild episodes of mural
thrombosis in response to subclinical rupture [28], leading
to repeated incorporation of small thrombi and eventually
resulting in gradual progression of an atherosclerotic pla-
que [29]. This hypothesis is further supported by clinical
evidence showing that high fibrinogen levels are posi-
tively correlated with the extent of atheroma on coronary
angiography [11,14,30,31]. Another study that measured
the progress of carotid atherosclerosis by high-resolution
duplex ultrasound found a temporal relationship between
fibrinogen and advanced atherosclerosis rather than with
early (inflammatory) stages of the disease [13]. In addi-
tion, immunohistochemical studies have shown the pre-
sence of fibrinogen in atherosclerotic plaques, indicating
that fibrinogen may be directly involved in plaque pro-
gression [32].
According to autopsy studies [33], repeated, healed silent
plaque ruptures with incorporated organized thrombi are
predominantly found in patients with ACS, indicating
episodic plaque growth and thereby contributing toward
the progression of advanced atherosclerotic plaques in
these patients. This might explain the fact that we found
a positive association of fibrinogen with degree of cor-
onary atherosclerosis in ACS patients in particular.
Rupture-prone, soft, lipid-rich plaques have previously
been found to be more common in patients presenting
with ACS compared with SAP patients [34]. Taken
together with reported findings of increased fibrinogen
levels in patients with established advanced CAD [35,
36], the unstable lipid-rich plaques in ACS patients may
be more thrombogenic than stable FI plaques in SAP
patients [37,38]. Thus, ACS patients with increased
fibrinogen levels are likely to have experienced multiple
consecutive mild episodes of mural thrombosis pre-
viously, eventually leading to a higher degree of athero-
sclerotic plaque compared with SAP patients.
Another prothrombotic factor that we investigated was
PAI-1, which has led to paradoxical results in previous
studies [39]. Conflicting results exist with respect to the
role of PAI-1 in both promoting and preventing plaque
development because of its complex multilevel functions
[39,40]. We could not find higher or lower degree of
coronary plaque in patients with elevated levels of both
fibrinogen and PAI-1.
The observed associations of fibrinogen with degree of
atherosclerosis were not independent of CRP. CRP has
been associated with the presence and degree of ather-
osclerosis [23,41], and both fibrinogen and CRP are
linked to vascular inflammation [42,43]. In line with our
current results, Hartmann et al. [17] found a positive, but
not independent, correlation between fibrinogen levels
and plaque progression on IVUS. Furthermore, in our
study, a higher degree of atherosclerosis was present in
patients with both high levels of CRP and high levels of
fibrinogen, suggesting a synergistic effect on coronary
atherosclerosis.
Inflammatory processes result in the release of numerous
mediators, including IL-6, which is the principal pro-
coagulant cytokine [42]. Although the exact interaction is
unknown, it is suggested that IL-6 on its part can increase
plasma concentrations of both fibrinogen and CRP,
which further amplify inflammatory and procoagulant
responses [42]. However, as we have reported earlier, in
the current cohort, we found no associations between IL-
6 and coronary plaque characteristics [25]. Also, in the
current investigation, we could not find any trend toward
a higher degree of coronary atherosclerosis in patients
with both high fibrinogen and high IL-6 levels.
Finally, our data suggest that fibrinogen may be asso-
ciated with the incidence of all-cause mortality or ACS.
The fact that the association became nonsignificant after
adjustment for age and sex may have resulted from lim-
ited statistical power (56 events after 1-year of follow-up)
as the effect estimate remained large after adjustment.
However, after additional adjustment for CRP, the
associations disappeared completely. Again, common
inflammatory grounds may have played a role here.
Although population-based studies have shown that
fibrinogen is associated with adverse outcome indepen-
dent of CRP [1], studies in patients with known CAD are
fewer in number [4,5,44] and not all of them have taken
CRP into account.
Some limitations of this study must be acknowledged.
First, the possibility that fibrinogen as an acute-phase
reactant may be the result of clinical presentation rather
than its cause, particularly in patients with ACS, cannot
be excluded. Our study design does not enable causal
inference. Nevertheless, our study does provide novel
data on fibrinogen in relation to in-vivo assessment of the
arterial wall (i.e. more accurate measures of coronary
atherosclerosis) [45] and may thus serve to be hypothesis
generating. Second, VH-IVUS imaging data were
acquired in a nonculprit coronary artery segment only.
This approach was based on the hypothesis that such a
nonculprit target segment adequately reflects the
patient’s overall state of coronary wall pathophysiology of
the larger coronary vasculature [19]. This hypothesis has
been confirmed by several IVUS studies that showed that
the coronary wall of a nonculprit segment in a single
vessel does reflect larger coronary disease burden and is
associated with subsequent cardiovascular events [46,47].
In conclusion, our findings support the hypothesis that
fibrinogen is associated with coronary atherosclerotic PB,
especially in patients presenting with ACS. However,
30 Coronary Artery Disease 2017, Vol 28 No 1
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whether this association is independent of CRP may be
questioned and warrants further investigation.
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